Stay updated on MAPP2 MDMA Therapy Clinical Trial
Sign up to get notified when there's something new on the MAPP2 MDMA Therapy Clinical Trial page.

Latest updates to the MAPP2 MDMA Therapy Clinical Trial page
- Check7 days agoChange DetectedThe page shows Revision: v3.5.5, replacing v3.5.4, indicating a small update to the study record's metadata rather than substantive content changes.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe study record version was updated from v3.5.3 to v3.5.4, representing a minor maintenance update to the ClinicalTrials.gov page. This change does not alter the study design, endpoints, eligibility criteria, or reported information.SummaryDifference0.0%

- Check43 days agoChange DetectedThe sponsor line now shows Resilient Pharmaceuticals as sponsor and responsible party, replacing Lykos Therapeutics. This change reflects a shift in the organization overseeing the study.SummaryDifference0.2%

- Check50 days agoChange DetectedThe page’s footer revision marker was updated from v3.5.2 to v3.5.3, indicating a general platform/version change without affecting the listed clinical trial study information.SummaryDifference0.0%

- Check57 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check86 days agoChange DetectedTemplate revision updated to v3.5.0, replacing v3.4.3. No user-facing content or study data are affected.SummaryDifference0.0%

Stay in the know with updates to MAPP2 MDMA Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MAPP2 MDMA Therapy Clinical Trial page.